Live from ash 2024 | oral report features encouraging data of ascentage pharma's bcl-2 inhibitor lisaftoclax in r/r mm, including a median pfs over 9 months

Rockville, md. and suzhou, china , dec. 10, 2024 /prnewswire/ -- ascentage pharma (6855.hk), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released the latest clinical data of its novel bcl-2 selective inhibitor, lisaftoclax (apg-2575), in patients with relapsed/refractory (r/r) multiple myeloma (mm) or immunoglobulin light-chain (al) amyloidosis, in an oral report at the 66th american society of hematology (ash) annual meeting, taking place in san diego, ca, the united states.
ASH Ratings Summary
ASH Quant Ranking